BSX Boston Scientific Corporation

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * Mirviss Jeffrey B.	2. Issuer Name and Ticker or Trading Symbol BOSTON SCIENTIFIC CORP [ BSX ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) EVP&Pres, Periph Intervent
(Last)          (First)          (Middle) 300 BOSTON SCIENTIFIC WAY	3. Date of Earliest Transaction (MM/DD/YYYY) 4/15/2021
(Street) MARLBOROUGH, MA 01752-1234 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	4/15/2021		M(1)		28123.0000	A	$6.2800	167281.0000	D
Common Stock	4/15/2021		S(1)		28123.0000	D	$40.9501 (2)	139158.0000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$6.2800	4/15/2021		M (1)			28123.0000	(3)	2/27/2022	Common Stock	28123.0000	$0.0000	0.0000	D

Explanation of Responses:
(1)	This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan.
(2)	Represents the weighted average sale price. These shares were sold in multiple transactions at $40.95 and $40.955. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
(3)	Grant to the reporting person of an option to purchase 28,123 shares of common stock vesting in four equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Mirviss Jeffrey B. 300 BOSTON SCIENTIFIC WAY MARLBOROUGH, MA 01752-1234			EVP&Pres, Periph Intervent

Signatures
/s/ Vance R. Brown, Attorney-in-fact		4/16/2021
**Signature of Reporting Person		Date